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. Previously, rare mutations in low-density lipoprotein (LDL) genes have been shown to contribute to MI risk in individual families [3] [4] [5] [6] [7] [8] , whereas common variants at more than 45 loci have been associated with MI risk in the population [9] [10] [11] [12] [13] [14] [15] . Here we evaluate how rare mutations contribute to early-onset MI risk in the population. We sequenced the protein-coding regions of 9,793 genomes from patients with MI at an early age (#50 years in males and #60 years in females) along with MI-free controls. We identified two genes in which rare codingsequence mutations were more frequent in MI cases versus controls at exome-wide significance. At low-density lipoprotein receptor (LDLR), carriers of rare non-synonymous mutations were at 4.2-fold increased risk for MI; carriers of null alleles at LDLR were at even higher risk (13-fold difference). Approximately 2% of early MI cases harbour a rare, damaging mutation in LDLR; this estimate is similar to one made more than 40 years ago using an analysis of total cholesterol 16 . Among controls, about 1 in 217 carried an LDLR coding-sequence mutation and had plasma LDL cholesterol . 190 mg dl 21 . At apolipoprotein A-V (APOA5), carriers of rare non-synonymous mutations were at 2.2-fold increased risk for MI. When compared with non-carriers, LDLR mutation carriers had higher plasma LDL cholesterol, whereas APOA5 mutation carriers had higher plasma triglycerides. Recent evidence has connected MI risk with coding-sequence mutations at two genes functionally related to APOA5, namely lipoprotein lipase 15, 17 and apolipoprotein C-III (refs 18, 19) . Combined, these observations suggest that, as well as LDL cholesterol, disordered metabolism of triglyceride-rich lipoproteins contributes to MI risk.
The US National Heart, Lung, and Blood Institute's exome sequencing project (ESP) sought to use exome sequencing as a tool to identify genes and mechanisms contributing to heart, lung and blood disorders. Within this program, we designed a discovery study for the extreme phenotype of early-onset MI (Fig. 1) , as heritability is substantially greater when MI occurs early in life 1, 2 . From eleven studies, we identified 1,088 cases with MI at an early age (MI in males #50 years old and in females #60 years old). As a comparison group, we selected 978 participants from prospective cohort studies who were of advanced age (males $60 years old or females $70 years old) and free of MI.
We sequenced cases and controls to high coverage by performing solution-based hybrid selection of exons followed by massively parallel sequencing (see Methods) 20 . We performed several quality control steps to identify and remove outlier samples and variants (see Methods and Supplementary Figs 1-13) . Characteristics of the discovery set of 1,027 cases and 946 controls are provided in Supplementary Tables 1-3 . Across the autosomes, each participant had an average of 43 nonsense, 7,828 missense, 92 splice-site, 189 insertion or deletion (indel) frameshift, 366 indel non-frameshift, and 103 non-synonymous singleton variants.
We first tested whether low-frequency coding variants (defined here as a single nucleotide variant (SNV) or indel with minor allele frequency (MAF) between 1% and 5%) are associated with risk for MI in the discovery sequencing study. We observed no significant association of MI status with any individual variant ( Supplementary Fig. 14) . We next evaluated the hypothesis that rare alleles (defined here as a SNV or indel with MAF ,1%) collectively within a gene contribute to risk for MI (see Methods). We tested for an excess (or deficit) in cases versus controls of rare, non-synonymous mutations by aggregating together SNVs and indels with MAF ,1% ('T1' test) in each gene and comparing the counts in cases and controls 21 . Empirical P values were obtained using permutation.
The need to aggregate rare variants requires consideration of which variants to be studied together. Ideally, one would aggregate only harmful alleles and ignore benign alleles. To enrich for harmful alleles, we considered three sets of variants: (1) non-synonymous only; (2) a 'deleterious (PolyPhen)' set consisting of non-synonymous after excluding missense alleles annotated as benign by PolyPhen-2 HumDiv software; and (3) 'disruptive' mutations only (nonsense, indel frameshift, splicesite; also referred to as 'null' mutations). To account for multiple testing, we set exome-wide significance for this study at P 5 8 3 10
27
, a Bonferroni correction for the testing of ,20,000 genes and three variant sets. When the T1 test was applied across these three sets of alleles in the discovery sequencing study, no gene-based association signal deviated from what we expected by chance We followed up on discovery sequencing results in four ways: (1) statistical imputation; (2) array-based genotyping using the Illumina HumanExome Beadchip ('Exome' chip); (3) targeted re-sequencing; and (4) additional exome sequencing (Fig. 1 ). Imputation and array-based genotyping were used to mainly evaluate low-frequency variants, whereas targeted re-sequencing and exome sequencing were used to test the role of rare mutations.
With the first and second follow-up approaches: imputation (n 5 64,132) and array-based genotyping (n 5 15,936), respectively, we did not identify novel low-frequency variants associated with MI or coronary artery disease (CAD) (see Methods, Supplementary Tables 4-7 and Supplementary Figs 23-27 ). The top association results for SNVs from array-based genotyping are shown in Supplementary Table 8 .
In the third follow-up approach, we re-sequenced several genes in additional cases and controls (see Methods, Supplementary Table 9) . After sequencing the exons of APOA5 in 6,721 cases and 6,711 controls, we identified 46 unique non-synonymous or splice-site SNVs or indel frameshifts with allele frequency , 1% (Supplementary Table 10 ). Based on these variants, we observed 93 alleles in cases and 42 alleles in controls (P 5 5 3 10 27 ; Table 1 , Fig. 2 and Supplementary Table 10 ). This burden of rare mutation signal was primarily driven by mutations seen in one or two study participants ( Fig. 2 and Supplementary Table 10 ). Carriers of a rare APOA5 mutation had a 2.2-fold higher risk for MI/ CAD than non-carriers (Table 1) .
According to a recent report, consideration of variant sets based on multiple protein prediction algorithms might yield stronger association signals 22 . Therefore, we investigated two additional variant sets: (1) 'deleterious (broad)' as defined by nonsense, splice-site, indel frameshift, Q313X   Q295X   T292I   R282C  R289C   Q283R   V281M   E279D   L277P   P272Q   A262S   R259S   E255G  E255G  E255K   I246M   P215L   V213M   G185C   G175A   E168D   E99K   E98D   Q97X   R94W   R40M  R40M   D37E  D37E   M92fs  R93Q   L60H   R94W   Q97X   Q95X   E98D  E99K  A105S  E116X  R143fs  Q145R  G164R   Q145R   G185C  S197G   R233W  R245C   A222V   P215L   H321L   P319L   G334V  R343C  L363Q   E81K   A315V   H321L   L363R   93 Individual mutations (non-synonymous, indel frameshift and splice-site variants with minor allele frequency less than 1%) are depicted according to the genomic position along the length of the APOA5 gene starting at the 59 end (top). The number of circles on the left and right represents the number of times that mutation is observed in cases or controls, respectively. Dashed lines across the gene connect the same mutation seen in both cases and controls. Mutations are shaded in red (observed in cases only), blue (observed in controls only) or yellow (observed in both cases and controls). Summary allele counts and carrier frequencies are shown. Only SNVs and indels with minor allele frequency less than 1% were considered in burden analysis. Deleterious (PolyPhen) as defined by nonsense, splice-site, indel frameshift, and missense annotated as 'possibly damaging' or 'probably damaging' by PolyPhen-2 HumDiv software; 'deleterious (broad)' as defined by nonsense, splice-site, indel frameshift, and missense annotated as deleterious by at least one of the five protein prediction algorithms of LRT score, MutationTaster, PolyPhen-2 HumDiv, PolyPhen-2 HumVar and SIFT; 'deleterious (strict)' as defined by nonsense, splice-site, indel frameshift, and missense annotated as deleterious by all five protein prediction algorithms; Disruptive defined as nonsense, splice-site or indel frameshift; T1: alleles from SNVs or indels with minor allele frequency less than 1%; Freq (%): percentage of cases or controls carrying a T1 allele; OR: odds ratio. Table 12 ).
In the fourth follow-up approach, we performed exome sequencing in additional early-onset MI/CAD cases and controls, bringing the total number of exomes analysed to 9,793 (Supplementary Tables 13  and 14) . We tested for an excess (or deficit) in cases versus controls of rare mutations in any gene ( Supplementary Fig. 28 and Supplementary Tables [15] [16] [17] . At this sample size, rare alleles collectively conferred risk for MI at exome-wide significance in only one gene, LDLR (Fig. 3) .
After sequencing the exons of LDLR in 4,703 cases and 5,090 controls, we identified 156 unique non-synonymous, splice-site SNVs and indel frameshifts with allele frequency ,1% (Table 2 and Supplementary Table 18 ). Of these variants, we observed 285 alleles in cases (6.1% of cases) and 208 alleles in controls (4.1% of controls) (1.5-fold effect size, P 5 4 3 10 26 ) ( Table 2 ). When restricting analysis to the deleterious (PolyPhen) set, 3.1% of cases and 1.3% of controls carried at least one such rare mutation, for a 2.4-fold effect size (P 5 1 3 10 211 ). A higher effect size of 4.2-fold (P 5 3 3 10
211
) was observed when restricting to the deleterious (strict) set. When restricting to disruptive alleles, 0.51% of cases and 0.04% of controls carried at least one such rare disruptive mutation, for a 13-fold effect size (P 5 9 3 10 25 ) ( Table 21 ). Using these rare variant signals as a guide, we estimated sample sizes that will be required to make similar discoveries. A very large number of samples, at least 10,000 exomes, are required to achieve 80% statistical power at an exome-wide level of statistical significance ( Supplementary  Figs 29-31 ).
Here we show that a burden of rare alleles in two genes, LDLR and APOA5, contributes to risk for MI. These results suggest several conclusions regarding the inherited basis for MI and rare variant association studies. First, after a DNA sequence-based search across nearly all proteincoding genes in .9,700 early-onset MI cases and controls, LDLR is the strongest association signal, with mutations in the gene accounting for about 2% of cases. In 1973, Goldstein and colleagues studied survivors of early MI and noted two common lipid abnormalities: hypercholesterolemia and hypertriglyceridemia 16 . On the basis of a total cholesterol value exceeding ,285 mg dl
21
, it was estimated that 4.1% of cases with MI prior to the age of 60 had familial hypercholesterolemia; this original estimate is similar to ours based on direct sequencing. In contrast, the prevalence of harmful LDLR mutations in the general population is higher than the original estimate (,0.5 in the present study versus 0.1-0.2% by Goldstein). Second, the rare variant association signal presented here establishes APOA5 as a bona fide MI gene. Initially discovered through comparative genomics analysis of a region harbouring several lipid regulators (that is, APOA1 and APOC3), the APOA5 locus harbours common variants associated with plasma triglycerides 24 . Candidate gene and genome-wide association studies have associated common variants at this locus also with MI risk (that is, 21131T.C, APOA5 promoter region, rs662799, MAF of 8%) 25, 26 . However, because of extensive linkage disequilibrium in this region, it had been previously uncertain which gene is responsible for the association with MI. The identification of multiple coding sequence variants within APOA5 clarifies that this gene contributes to MI risk in the population. Third, these data point to a route to MI beyond LDL cholesterol, namely triglyceriderich lipoproteins 27 and the lipoprotein lipase pathway. Genetic variation at two other proteins related to APOA5 function, apolipoprotein C-III (refs 18, 19, 28) and lipoprotein lipase 15, 17 , has been associated with triglycerides and MI risk. Finally, the present study makes clear that rare variant discovery for complex disease will require the sequencing of thousands of cases and careful statistical analysis. Two reasons for the large sample size requirement are an inability to readily distinguish harmful from benign alleles and the extreme rarity of harmful alleles.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Summary allele counts and carrier frequencies are shown. Only SNVs and indels with minor allele frequency less than 1% were considered in burden analysis. Deleterious (PolyPhen) as defined by nonsense, splice-site, indel frameshift, and missense annotated as 'possibly damaging' or 'probably damaging' by PolyPhen-2 HumDiv software; 'deleterious (broad)' as defined by nonsense, splice-site, indel frameshift, and missense annotated as deleterious by at least one of the five protein prediction algorithms of LRT score, MutationTaster, PolyPhen-2 HumDiv, PolyPhen-2 HumVar and SIFT; 'deleterious (strict)' as defined by nonsense, splice-site, indel frameshift, and missense annotated as deleterious by all five protein prediction algorithms; Disruptive defined as nonsense, splice-site or indel frameshift; T1: alleles from SNVs or indels with minor allele frequency less than 1%; Freq (%): percentage of cases or controls carrying a T1 allele; OR: odds ratio. . Briefly, the goal of the NHLBI ESP was to discover rare coding variation in genes contributing to heart, lung and blood disorders using next-generation sequencing of the protein-coding regions of the genome (exome sequencing). The study includes five primary groups including: Seattle GO (University of Washington, Seattle, Washington); Broad GO (Broad Institute, Cambridge, Massachusetts); WHISP (Ohio State University Medical Center, Columbus, Ohio); Lung GO (University of Washington, Seattle, Washington); Heart GO (University of Virginia Health System, Charlottesville, Virginia) and two collaborating groups, WashU GO (Washington University, St Louis) and CHARGE-S GO (University of Texas Health Sciences Center, Houston, Texas).
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We General overview of the ESP early-onset myocardial infarction study. Within the NHLBI ESP, we designed an exome sequencing experiment specifically to study early-onset myocardial infarction (EOMI). We selected EOMI cases and controls from eleven studies, including: ARIC, MESA, CCGB, FHS, HARPS, MGH PCAD, PennCath, TRIUMPH, WHI, CHS, and JHS ( Supplementary Tables 1-3 ). Samples were selected based on the extreme tails of the phenotypic distribution, in order to enrich for a genetic contribution to disease. EOMI cases were defined as individuals who had an MI at an age of #50 for men and #60 for women. Controls were selected as individuals with no history of MI at baseline or during follow-up to at least age 60 for men and 70 for women. The study samples, along with case and control definitions, are briefly described below and shown in Supplementary Tables 1-3 . Study and phenotype descriptions for ESP EOMI The HeartGO consortium. HeartGO is a multiethnic consortium consisting of six NHLBI population-based cohorts of men and women: ARIC, CHS, FHS, CARDIA, JHS, and MESA. The age range of participants in these six cohorts spans the spectrum from early adulthood to old age, providing a broad age representation. Each participating cohort in HeartGO has completed ascertainment of multiple phenotypes, including all of the major cardiovascular risk factors (blood pressure, lipids, diabetes status), biomarkers including measures of blood cell counts, subclinical disease imaging, and cardiovascular and lung outcomes including MI and stroke. Participants in all six cohorts provided written informed consent. The NIH database of genotypes and phenotypes (dbGaP) site contains further details regarding the phenotypes accessible for each individual HeartGO cohort. Cleveland Clinic GeneBank (CCGB). The CCGB study is a single-centre prospective cohort-based study that enrolled patients undergoing elective diagnostic coronary angiography between 2001 and 2006. Heart Attack Risk in Puget Sound (HARPS). The HARPS study is a populationbased case-control study that enrolled cases with incident MI presenting to a network of hospitals in the metropolitan Seattle-Puget 30 and all patients had an elevated troponin blood test. Women's Health Initiative (WHI). WHI is a major research program that has been ongoing for over 20 years to address the most common causes of death, disability and poor quality of life in postmenopausal women-cardiovascular disease, cancer, and osteoporosis. Studies involved in follow-up statistical imputation, array-based genotyping, targeted re-sequencing and additional exome sequencing Statistical imputation. We performed statistical imputation of single nucleotide variants (SNVs) discovered in the exomes of the first 786 samples. We imputed exonic SNVs into 64,132 independent samples in 16 studies to test for association of coding SNVs with MI or CAD. The studies are described in Supplementary Table 5 . Array-based genotyping. We performed follow-up array-based genotyping using the Illumina HumanExome Beadchip ('exome chip') array in 15,936 independent samples from seven studies. The studies are described in Supplementary Table 7 . Targeted re-sequencing. We performed targeted re-sequencing of the APOA5 gene in an additional 11,414 individuals from five cohorts. The studies are described in Supplementary Table 9 . Exome sequencing-based follow-up. We performed exome sequencing in additional individuals from three cohorts. The studies are described in Supplementary  Table 13 .
Detailed methods for the processing and analysis of samples for the various stages of the project are described below. We describe methods for the different stages of the project, including discovery exome sequencing, follow-up imputation, arraybased genotyping, targeted re-sequencing and additional exome sequencing. Laboratory methods for discovery exome sequencing in the ESP EOMI Project. Exome sequencing. Exome sequencing was performed at the Broad Institute. Sequencing and exome capture methods have been previously described 29 . A brief description of the methods is provided below. Receipt/quality control of sample DNA. Samples were shipped to the Biological Samples Platform laboratory at the Broad Institute of MIT and Harvard. DNA concentration was determined by the Picogreen assay (Invitrogen) before storage in 2D-arcoded 0.75 ml Matrix tubes at 220 uC in the SmaRTStore (RTS, Manchester, UK) automated sample handling system. We performed initial quality control (QC) on all samples involving sample quantification (PicoGreen), confirmation of highmolecular weight DNA and fingerprint genotyping and gender determination (Illumina iSelect). Samples were excluded if the total mass, concentration, integrity of DNA or quality of preliminary genotyping data was too low. Library construction and in-solution hybrid selection. Starting with 3 mg of genomic DNA, library construction and in-solution hybrid selection were performed as described previously 31 . A subset of samples, however, was prepared using this protocol with some slight modifications. Initial genomic DNA input into shearing was reduced from 3 mg to 100 ng in 50 ml of solution. In addition, for adaptor ligation, Illumina paired-end adapters were replaced with palindromic forked adapters with unique 8 base index sequences embedded within the adaptor. Preparation of libraries for cluster amplification and sequencing. After insolution hybrid selection, libraries were quantified using qPCR (KAPA Biosystems) with probes specific to the ends of the adapters. This assay was automated using Agilent's Bravo liquid handling platform. Based on qPCR quantification, libraries were normalized to 2 nM and then denatured using 0.1 N NaOH using PerkinElmer's MultiProbe liquid handling platform. A subset of the samples prepared using forked, indexed adapters was quantified using qPCR, normalized to 2 nM using Perkin-Elmer's Mini-Janus liquid handling platform, and pooled by equal volume using the Agilent Bravo. Pools were then denatured using 0.1 N NaOH. Denatured samples were diluted into strip tubes using the Perkin-Elmer MultiProbe. Cluster amplification and sequencing. Cluster amplification of denatured templates was performed according to the manufacturer's protocol (Illumina) using either Genome Analyzer v3, Genome Analyzer v4, or HiSeq 2,000 v2 cluster chemistry and flowcells. After cluster amplification, SYBR green dye was added to all flowcell lanes, and a portion of each lane visualized using a light microscope, in order to confirm target cluster density. Flowcells were sequenced either on Genome Analyzer II using v3 and v4 Sequencing-by-Synthesis Kits, then analysed using RTA v1.7.48, or on HiSeq 2,000 using HiSeq 2,000 v2 Sequencing-by-Synthesis Kits, then analysed using RTA v1.10.15. All samples were run on 76 cycle, paired end runs. For samples prepared using forked, indexed adapters, Illumina's Multiplexing Sequencing Primer Kit was also used. Read mapping and variant analysis. Samples were processed from real-time basecalls (RTA 1.7 software [Bustard], converted to qseq.txt files, and aligned to a human reference (hg19) using Burrows-Wheeler Aligner (BWA, see ref. 32) . Aligned reads duplicating the start position of another read were flagged as duplicates and not analysed ('duplicate removal'). Data was processed using the Genome Analysis ToolKit (GATK v1.1.3, ref. 33 ). Reads were locally realigned (GATK IndelRealigner) and their base qualities were recalibrated (GATK TableRecalibration). Variant detection and genotyping were performed on both exomes and flanking 50 base pairs of intronic sequence using the UnifiedGenotyper (UG) tool from the GATK. Variant data for each sample was formatted (variant call format (VCF)) as 'raw' calls for all samples. SNVs and indel sites were flagged using the variant filtration LETTER RESEARCH walker (GATK) to mark sites of low quality that were likely false positives. SNVs were marked as potential errors if they exhibited strong strand bias (SB $ 0.10), low average quality (quality per depth of coverage (QD) , 5.0), or fell in a homopolymer run (HRun . 4). Indels were marked as potential errors for low quality (quality score (QUAL) , 30.0), low average quality (QD ,2.0), or if the site exhibited strong strand bias (SB . 21.0). Samples were considered complete when exome targeted read coverage was $ 203 over $ 80% of the exome target. Data analysis QC. Fingerprint concordance between sequence data and fingerprint genotypes was evaluated. Variant calls were evaluated on both bulk and persample properties: novel and known variant counts, transition-transversion (TS-TV) ratio, heterozygous-homozygous non-reference ratio, and deletion/insertion ratio. Both bulk and sample metrics were compared to historical values for exome sequencing projects at the Broad Institute. No significant deviation of the ESP variants or ESP samples from historical values was noted. Data processing, quality control and association analysis of discovery exome sequencing Variant calling. Variants (SNVs and indels) were identified and genotyped from recalibrated BAM files 34 using the multi-sample processing mode of the Unified Genotyper tool from the GATK. Variants were first identified and genotyped in random batches of 100 samples. The batches were then merged into a single VCF file using the GATK CombineVariants tool. Variant annotation. Variants (SNVs and indels) were annotated using the GRCh37.64 database using the SNP effect predictor tool (SnpEff, see ref. 35 ) and the GATK VariantAnnotator. The primary SnpEff genomic effects that were annotated include: splice-site acceptor, splice-site donor, indel frameshift, indel non-frameshift, nonsense, non-synonymous and synonymous variants. For variants that have different annotations due to multiple transcripts of the gene, the highest impact effect for each variant was taken. Sample level quality control. We performed several quality control steps to identify and remove outlier samples (Supplementary Figs 1-8) . First, we required that each sample had a minimum of 20-fold coverage for at least 80% of the targeted bases. Second, we compared self-reported ancestry with that inferred from the sequence data and removed discordant samples. Third, we removed samples with high degree of heterozygosity and low number of singleton counts as this pattern suggests DNA contamination across samples. Fourth, we removed samples with an extremely high number of variants or singletons as this can suggest low quality DNA. Finally, we removed samples exhibiting a mismatch between the reported gender and that inferred from sequence data. Of 2,066 cases and controls sequenced across the exome, we removed 93 samples due to these exclusion criteria. Variant level quality control. QC measures were also performed to remove low quality variants. We assessed population genetics metrics including the TS-TV ratio, the ratio of the number of heterozygous changes to the number of homozygous nonreference changes, and the number of non-synonymous to the number of synonymous changes. This analysis can help filter false positive calls since we expect the true TS-TV to be around ,3.2 in European populations 33 , while a set of random SNVs (or false positive variants) should give a random expectation of 0.5. Variants with low depth of coverage (DP) and high percent missingness generally had low TS-TV and heterozygous-homozygous non-reference ratios. Variants were removed if there was DP ,8 average per sample and .2% missingness (Supplementary Figs  9-12 ). Distribution of allele frequencies of the SNVs is shown in Supplementary  Fig. 13 . Common variant association analysis. We performed single variant association analysis in our exome sequencing data set. For SNVs with MAF greater than 5%, we ran logistic regression, after adjusting for 10 principal components while for SNVs with MAF less than 5%, we ran Fisher's Exact test. We performed association analysis in European Americans and African Americans separately and then performed sample size weighted meta-analysis using METAL 36 . The association results are shown in Supplementary Fig. 14 . Rare variant association analysis. To test whether rare mutations contribute to MI, we performed burden of rare variant analysis on the ,2,000 ESP EOMI exome samples. We performed a variant of the Combined Multivariate Collapsing test 21 , that groups the count of alleles of SNVs in cases and controls. Phenotype labels were permuted 100,000 times to assign a statistical significance. We accounted for ethnicity by permuting phenotype labels within each ethnicity. Association analysis was performed using PLINK/SEQ.
We collapsed variants based on computational predictions from PolyPhen-2 HumDiv 37 . Minor allele frequencies were calculated from all available samples sequenced in each study in order to obtain the most accurate MAF estimates. Therefore, calculation of MAF for ESP EOMI 1 and 2 was performed on a larger set of exome samples that were sequenced at the Broad Institute as part of ESP (n 5 970 exomes for ESP EOMI 1 and n 5 3,014 for ESP EOMI 2). For our burden of rare variant association analysis, we use a MAF threshold of 1% (T1). Furthermore, we use three different types of variant groupings when collapsing by gene.
These variant groups are: (1) non-synonymous only; (2) a deleterious set consisting of non-synonymous after excluding missense alleles annotated as benign by PolyPhen-2 HumDiv software; and (3) disruptive (nonsense, indel frameshift, splice-site) mutations only. We also performed the T1 test after collapsing all non-synonymous mutations by KEGG pathways (Supplementary Figs 21 and 22) . Methods for follow-up statistical imputation Construction of reference panels and targeted imputation panels. Exome imputations were performed using two reference panels and 16 targeted imputation panels. A total of 697 ESP samples (436 African Americans and 261 European Americans) were used for the first reference panel while 89 samples from the 1000 Genomes Project 38 were drawn for the second reference panel. For the ESP reference panel, all samples from ARIC (n 5 212), JHS (n 5 119), MGH PCAD or HARPS (n 5 151) and WHI studies (n 5 41) were genotyped using commercially available Affymetrix 6.0 arrays. Samples from the FHS (n 5 174) were genotyped using the Affymetrix 5.0 array. The second reference panel was comprised of samples from the 1000 Genomes Project that had genotype data for both low coverage sequencing and high coverage exome sequencing data 38 . A total of 89 samples were selected from 6 diverse populations (23 African Ancestry in Southwest US (ASW), 9 Utah residents with Northern and Western European ancestry (CEU), 12 Colombian in Medellin, Colombia (CLM), 25 Mexican Ancestry in Los Angeles, CA (MXL), 17 Toscani in Italia (TSI) and 3 Yoruba in Ibadan, Nigeria (YRI) samples). Low-coverage whole genome sequencing, high-coverage exome sequencing and targeted exome capture were performed based on standard protocols at the Broad Institute. Details of the sequencing methods and samples have been described previously 38 . Imputation was performed into 16 independent study samples with genome-wide genotype data. Study samples were genotyped using commercially available Affymetrix or Illumina genotyping arrays. Further details are described in Supplementary Table 5 .
Reference panels were created by merging genotypes from SNVs that span the entire genome (hence, providing a haplotype 'scaffold'), with genotypes from SNVs from ESP exome sequencing data. The first reference panel was generated using genotypes from both genome-wide SNV arrays obtained from dbGAP and exome sequencing data. The second reference panel was generated using genotype data for both low coverage sequencing and high coverage exome sequencing data. Both the reference panel and targeted genome-wide panel were phased using the 'best guess haplotypes' option in IMPUTE2 (ref. 39) . Haplotype phasing were performed in 5 megabase chunks as recommended by the software tutorial 39 .
Data processing, quality control and association analysis. Imputation of the exome was performed using IMPUTE2. We imputed approximately 400,000 coding SNVs from the reference panels into 28,068 cases and 36,064 controls from 16 different study samples with genome-wide data. Descriptions for the study samples have been reported elsewhere (Supplementary Table 5 for references). We filtered SNVs with MAF , 1% and imputation quality (INFO) ,0.5 from further analysis. The distribution of imputation qualities of the SNVs is shown in Supplementary  Figs 23 and 24 . Association testing for CAD/MI was performed using the score method and assuming an additive model in SNPTEST 40 . Age, sex and the first two principal components were used as covariates when appropriate. We did not observe any indication of excess inflation of test statistics in any of the study samples (Supplementary Table 22 ). Meta-analysis of study-specific P values for imputed SNVs was performed using the Z-score method weighted by sample size in METAL. Beta and standard errors were estimated based on an inverse-weighted meta-analysis. The distribution of association results for the imputation results is shown in Supplementary Fig. 25 and top association results in Supplementary Table 6 . Methods for follow-up array-based genotyping Laboratory methods. DNA samples were sent to the Broad Institute Genetic Analysis Platform for genotyping and were placed on 96-well plates for processing using the Illumina HumanExome v1.0 SNP array. Genotypes were assigned using GenomeStudio v2010.3 using the calling algorithm/genotyping module version 1.8.4 along with the custom cluster file StanCtrExChp_CEPH.egt. Only samples passing an overall call rate of 98% criteria and standard identity check were released from the genetic analysis platform. Data processing, quality control and association analysis. To identify single lowfrequency SNVs associated with MI or CAD, we performed array-based genotyping using the Illumina Human Exome Beadchip. We genotyped 83,680 sites identified from exome sequencing in 1,027 early-onset MI cases and 946 controls. The samples for genotyping were drawn from the cohorts listed in Supplementary Table 7 and have been previously described. The functional effect of each variant was predicted using the SeattleSeq Annotation server. For variants having more than one functional class, the most deleterious class was retained.
Several quality control processes were employed to ensure high quality genotypes and samples were used in the association analysis. Samples were excluded for the following criteria: greater than 5% missing genotypes; discordance between inferred gender based on genotype and self-reported gender; inbreeding coefficient less than 20.2 or greater than 0.2; duplicated samples; or proportion of genotypes RESEARCH LETTER identical by descent .0.2. In addition, principal components were calculated using Eigenstrat 4.2 (ref. 41 ) and samples were removed if they were found to be statistical population outliers. Variants were removed for the following criteria: MAF 5 0%; significant difference between missingness in cases compared with controls; extreme deviation from Hardy-Weinberg equilibrium (P , 1 3 10
26
); or significant association with genotyping plate assignment. All quality control filtering were performed using PLINK 42 and R (The R Project for Statistical Computing, Vienna, Austria).
Association testing for CAD/MI was performed within each study separately using logistic regression with ten principal components of ancestry as covariates. An inverse standard-error weighted meta-analysis was performed to combine results across studies. The association testing was performed using PLINK 42 and the metaanalysis was performed using METAL. There was no indication of an inflation of test statistics across studies (Supplementary Table 23 ). The stability of logistic regression was assessed by examining the standard error of the beta estimate as a function of minor allele frequency (see Supplementary Fig. 32 ). As shown, logistic regression is unstable for a MAF , 0.05%. Fisher's Exact test was used for variants with MAF , 0.05%. The top association results are shown in Supplementary Table 8 .
Methods for follow-up re-sequencing Selection of genes. We first selected six associated genes (based on biologic and/or statistical evidence with T1 P , 0.005; APOA5, CHRM5, SMG7, LYRM1, APOC3, NBEAL1) for replication sequencing in the ATVB study (Supplementary Table 24) where all cases had suffered an MI before age of 46. We also pursued the same six genes in the Ottawa Heart Study with 552 cases and 586 controls (Supplementary Table 25 ). One of the genes (APOA5) continued to show significant results and was sequenced in three additional studies ( Table 1 and Supplementary Table 26 ). In total, we performed follow-up sequencing of APOA5 in six study samples, including the Verona heart study (VHS), Ottawa heart study (OHS), additional exomes from atherosclerosis, thrombosis, and vascular biology Italian study group (ATVB), additional exomes from the ESP EOMI study (ESP EOMI 2), Precocious Coronary Artery Disease Study (PROCARDIS), and the Copenhagen City Heart Study and Copenhagen Ischaemic Heart Disease Study (CCHS/CIHDS). Laboratory methods. For the VHS study, genomic DNA was extracted from white blood cells using the salting-out method. The protein-coding regions corresponding to the RefSeq transcripts NM_052968 for APOA5 and NM_012125 for CHRM5 were sequenced using in-house designed primers (available on request) and the BigDye Terminator Cycle Sequencing Kit v1.1 on an ABI-3130XL Genetic Analyzer (Applied Biosystems, Foster City, CA). SNVs were called using the Variant Reporter software v1.1 (Applied Biosystems).
For the OHS study, PCR primers were designed, tested and optimized to target the exons and flanking non-coding sequences for each gene. Sequencing reactions were performed using big dye terminator chemistry and chromatograms obtained with an Applied Biosystems ABI 3730XL capillary sequencer. Chromatograms were base-called by using Phred, assembled into contigs by using Phrap, and scanned for SNVs with PolyPhred 43 to identify polymorphic sites. Each read was trimmed to remove low-quality sequence (Phred score ,25), resulting in analysed reads with an average Phred quality of 40. After assembly and variant calling, each polymorphic site was reviewed by a data analyst using Consed 44 to ensure the quality and accuracy of the variant calls. This process generates sequence-based SNV genotypes with accuracy .99.9%.
For the PROCARDIS study, a single long range PCR product (LRPCR) was amplified to provide coverage of the APOA5 exonic, intronic and flanking sequences (human reference sequence NCBI build 37 chromosome 11:116,659,905-116,664,331). The LRPCR products were tagged with unique sequence (barcode) adaptors, and processed into 56 short amplicons (Reflex reactions, http://www.populationgenetics. com) and pooled for multiplex next-generation sequencing (NGS). NGS was performed on a MiSeq personal sequencer to .203 coverage across 95% of the APOA5 target region on 1,385 MI cases and 1,499 controls. Paired-end reads were mapped to NCBI build 37 using the BWA and SMALT aligners; variants were identified by the GATK unified genotyper (v1.6.13) and annotated using SnpEff v2.0.5 and the GRCh37.64 database.
For the CCHS/CIHDS study, lightscanner screening and re-sequencing were performed. Genomic DNA was isolated from frozen whole blood (QiaAmp4 DNA blood mini kit; QIAGEN, Hilden, Germany). Six PCR fragments were amplified covering the three coding exons and adjacent splice-sites (approximately 20 base pairs upstream and downstream each exon) of APOA5. Mutational analysis of the PCR products was performed by high-resolution melting curve (HRM) analysis using the Lightscanner system (Idaho Technology, Salt Lake City, Utah). PCR fragments showing heteroduplex formation by HRM analysis were subsequently sequenced on an ABI 3730 DNA analyser (Applied Biosystems, Foster City, CA). Data processing, quality control and association analysis. After sequencing, variants were annotated using SnpEff or Annovar 45 . For each study, only nonsynonymous SNVs with MAF ,1% were analysed. Rare variant burden testing was performed using the T1 test. Meta-analysis was performed to combine evidence across study specific P values using the sample size weighted Z-score method, implemented in METAL. Association results and a listing of APOA5 mutations discovered from sequencing are described in Table 1 and Supplementary Table 10 . P values for association between APOA5 mutation carrier status and lipid traits were performed using the Mann-Whitney ranksum test. Results are shown in Supplementary Table 12 . Methods for follow-up exome sequencing Laboratory methods. We performed follow-up exome sequencing in additional samples from three other studies. Sequencing was performed at the Broad Institute, using the same protocols described above for the NHLBI ESP Project. Data processing, quality control and association analysis. Variant calling and annotations were performed as described above for the NHBLI ESP EOMI. Quality control of samples was performed using the following steps. To detect mismatched samples, we calculated discordance rates between genotypes from exome sequencing with genotypes from array-based genotyping. We removed samples with discordance rate . 0.02. We tested for sample contamination using verifyBamID 46 , which examines the proportion of non-reference bases at reference sites. We removed samples with FREEMIX or CHIPMIX scores .0.2. Furthermore, we removed outlier samples with too many or too few SNVs (.700 or ,5 singletons, .400 or ,5 doubletons, .16,000 (.20,000 for African) or ,10,000 total SNVs), and those with too high or low TS-TV (.4 or ,3) and heterozygosity (heterozygote to homozygote non-reference ratio .6 or ,2). Finally, we removed samples with high missingness (.0.1). In total, 202 samples were removed. For quality control of variants, we removed SNVs and indels that had low recalibration scores after running GATK VariantRecalibrator. We also removed SNVs with low coverage (DP ,140,000 and quality over depth (QD) ,2) and high missingness (frequency of missing genotypes .0.02). For quality control of indels, we removed indels that had excessive strand bias (Fisher Strand .200) , high proportion of alternate alleles seen near the ends of reads (ReadPosRankSum ,220), deviation from HardyWeinberg equilibrium (InbreedingCoeff ,20.8) and low coverage (QD ,3). Rare variant association analysis was performed using EPACTS. We performed burden of rare variant analysis using the Efficient Mixed-Model Association eXpedited (EMMAX) Combined Multivariate and Collapsing (CMC) test 47 . This approach uses a kinship matrix to take into account population structure. We restricted analyses to SNVs and indels with minor allele frequency ,0.01. Furthermore, we restricted analyses to three different sets of variants: (1) non-synonymous only; (2) a deleterious set consisting of non-synonymous after excluding missense alleles annotated as benign by PolyPhen-2 HumDiv software; and (3) disruptive (nonsense, indel frameshift, splice-site) mutations only. Estimation of heritability explained by a burden of rare mutations in the APOA5 and LDLR genes. We calculated the heritability explained by a burden of rare mutations in the APOA5 and LDLR genes using the following assumptions. We assumed that the alleles come from a mixture of two distributions: harmless alleles, with no effect on the trait, and null alleles, which destroy the function of the gene and have an (constant) effect on the trait. We assumed different values for the fraction of null alleles, a (our current expectation for most genes for a is around one-third to one-half for missense alleles and here we clump missense alleles together with nonsense alleles, which should slightly increase a). The variance explained is sensitive to this parameter. We assumed a liability-threshold model for disease, with an underlying (un-observed) continuous trait representing risk for MI, and MI occurring if risk is above a certain threshold. We assume all null alleles have effect b (in units of standard deviations) on the liability scale. We assumed different values for the prevalence (denoted k) for early MI (3% to 5%). Results are somewhat sensitive to prevalence; higher prevalence will slightly increase heritability estimates. Given the prevalence, the number of carriers in cases and controls gives us the allele frequency in the population (which is very close to the allele frequency in controls).
We fitted the effect size (b on liability scale) and alleles for different values of a and k. Results for APOA5 are shown in Supplementary Table 11 and results for LDLR are shown in Supplementary Table 19 . For APOA5, b is moderate (up to roughly one standard deviation), with variance explained between 0.08% and 0.17% of the total phenotypic variance (on the liability scale). If we assume the heritability of MI is 50%, a burden of rare mutations in the APOA5 gene may explain 0.16-0.34% of the heritability. For LDLR, for all values, variance explained is between 0.13% and 0.32% of the total phenotypic variance (on the liability scale) and 0.26-0.64% of the heritability. Sample size extrapolations and power calculations for burden of rare variants. We evaluated the sample size that is needed to reach genome-wide significance levels (P 5 2.5 3 10
) for the T1 test. Our calculations relied on the following assumptions. We assumed that all allelic variants with population frequency less than 1% are causal and have identical effect sizes. We also assumed that all alleles with frequency greater than 1% were benign.
LETTER RESEARCH
Our calculations differentiate between the allele frequency of a SNV in our exome samples with its true allele frequency in a population. The T1 test compares the number of carriers of an allele for a SNV with sample (rather than population) allele frequency less than 1% among cases and controls. We considered three factors when extrapolating to larger sample sizes. First, we assumed our sample is comprised of 50% cases and 50% controls. As the prevalence of EOMI is estimated to be 5%, the sample frequency of causal alleles is likely to be higher than the population frequency. Second, some alleles with population frequency below 1% may, by chance, have sampling frequency greater than 1% and therefore be excluded from the test. Third, the true allele frequency of the SNVs in the population is unknown. In contrast to earlier work that relied on population genetics modelling 48 , we provide an update on the power needed to detect rare variant signal after considering the three factors above. We calculated liberal and conservative estimates for our sample size extrapolations and power calculations. The conservative estimate was based on the estimate of the total population frequency of all causal alleles (below 1%) that would be unlikely to be excluded from the T1 test due to the sampling frequencies exceeding 1%. Because allele frequency distribution is dominated by rare alleles, for an allele with population frequencyx, expected population allele frequency is smaller than x.
(E xjx ð Þvx) ð1Þ
Therefore, the expected total population frequency of all alleles below frequency x is smaller than the total sampling frequency of alleles below sampling frequencyx. However, settingx at 1% would result in a liberal rather than conservative estimate because alleles with population frequency below 1% may be excluded from the T1 test as having sampling frequency above 1%. This occurs due to oversampling cases (our sample has 50% of cases at disease prevalence of 5%) and sampling variance. For example, assuming only one causal allele per gene, the power of the T1 test is maximal for the population allele frequency close to 0.5% for a sample of 1,000 cases and 1,000 controls. For a sample of 10,000 individuals, the chance that a risk allele with population frequency of 0.5% would be excluded from the T1 test is below 10
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, making this threshold even more conservative. Therefore, for a conservative estimate, we have assumed that the total population frequency of all causal alleles per gene would equal the total sampling frequency of alleles below 0.5% in the ESP sample. Our liberal estimate assumed that all causal alleles will be included in the T1 test. We assumed that the total population frequency of all causal alleles per gene would equal the total sampling frequency of alleles below 1% in the ESP sample.
Once we extrapolated the number of mutation carriers to 20,000 samples, we then performed power calculations to see how many samples would be needed to reach a genome-wide significance level for the T1 test (P 5 2.5 3 10 26 after correcting for 20,000 genes). Power calculations were performed by first sampling a genotype at random from the pool of 20,000 simulated samples. Based on the T1 carrier status of the drawn sample, we simulated the phenotype based on a calculated probability. The phenotype was simulated based on a prevalence rate of 5% for disease, carrier status of the random sample and assumed relative risk of 2.0 of the mutation. For T1 carriers, the probability of being a case was calculated as relative risk (RR) of T1 carrier multiplied by prevalence rate of disease (RR * prevalence rate). For non-carriers, the probability of being a case was simply the prevalence rate. The case-control ratio was 1:1. We performed sample size extrapolations for genes with varying number of T1 mutations (25th percentile, median and 75th percentile of carriers with a T1 mutation for all genes discovered in the exome, Supplementary Figs 29-31 ).
